Pulmonary Cell News 7.36 September 13, 2018 | |
| |
TOP STORYNumerous irreversible EGFR tyrosine kinase inhibitors, including CO-1686 and osimertinib, synergized with MRX-2843 to inhibit wtEGFR non-small cell lung cancer cell expansion, irrespective of driver oncogene status. [Clin Cancer Res] Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Upon rhinovirus infection or RIG-I stimulation, nasal-derived epithelial cells exhibited much more robust antiviral responses than bronchial-derived cells. Conversely, RIG-I stimulation triggered more robust activation of the NRF2-dependent oxidative stress response in bronchial cells compared to nasal cells. [Cell Rep] Full Article | Press Release | Graphical Abstract Airway epithelial dysfunction is a feature of advanced lung disease, but the effect of hypercapnia on airway epithelium is unknown. Researchers examined the effect of normoxic hypercapnia vs normocapnia, on global gene expression in differentiated normal human airway epithelial cells. [Sci Rep] Full Article Investigators report that down-regulation of the p23 protein content in normal, untransformed human bronchial tracheal epithelial cells to 56% of its content also suppresses the aryl hydrocarbon receptor protein levels to 59% of the wild-type content. [Toxicol Sci] Abstract Exposure of cells to particulate matter 2.5 (PM2.5) at a concentration of 100 μg/mL for 24 hours was most effective for inhibiting cell viability. PM2.5 induced cell arrest in the G0/G1 phase and increased mitochondrial membrane potential, reactive oxygen species, and cell apoptosis with increasing concentration. [J Cell Biochem] Abstract Through the induction of epithelial-to-mesenchymal transition using TGF-β1, scientists demonstrated that mitochondrial functions were abnormal by increasing reactive oxygen species production and reducing mitochondrial membrane potential, ATP content and mitochondrial complex protein expression. [Free Radic Res] Abstract Suppression of NRF2/ARE by Convallatoxin Sensitizes A549 Cells to 5-FU-Mediated Apoptosis Researchers identified convallatoxin as a novel inhibitor of NF-E2-related factor 2 (NRF2)/antioxidant response element (ARE). Convallatoxin sensitized A549 cells to 5-fluorouracil-mediated cell death by promoting apoptosis. [Free Radic Res] Abstract LUNG CANCERScientists found the miR-30 family to be downregulated during the spheroid formation of non-small cell lung cancer (NSCLC) cells, and patients with lower miR-30a/c expression had shorter overall survival and progression-free survival. [Mol Ther] Abstract The authors found that lung cancer PC14PE6/AS2 (AS2) had higher mTOR and Akt and also lower PTEN expression than A549 cells. Descended autophagy was demonstrated with more decreased p62 accumulation and LC3 II conversion in AS2 cells as compared to A549 cells. [Cell Death Discov] Full Article Investigators showed that β-elemene inhibits the growth of lung cancer cells. Mechanistically, they found that β-elemene decreased the phosphorylation of signal transducer and activator of transcription 3 (Stat3) and miRNA155-5p mRNA but induced the protein expression of human forkhead box class O (FOXO)3a; the latter two were abrogated in cells with overexpressed Stat3. [Exp Mol Med] Full Article Scientists designed and prepared a fusion protein containing a human β-defensin-1 fragment and an epidermal growth factor receptor (EGFR)-targeting oligopeptide as well as lidamycin, an extremely potent cytotoxic antitumor antibiotic, which consists of an apoprotein and a highly active enediyne. [Lab Invest] Abstract Subscribe to one of our other 19 science newsletters such as Cancer Stem Cell News & Human Immunology News. | |
| |
REVIEWSImmune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer: Benefits and Pulmonary Toxicities The authors discuss management strategies for checkpoint inhibitor pneumonitis (CIP), including current consensus on management of steroid-refractory CIP. Given the nascent nature of this field, they highlight areas of uncertainty and emerging research questions in the burgeoning field of checkpoint inhibitor pulmonary toxicity. [Chest] Abstract Visit our reviews page to see a complete list of reviews in the pulmonary cell research field. | |
| |
INDUSTRY NEWSInnovent Biologics announced that the first patient has been dosed in a Phase III clinical trial studying sintilimab, a fully human anti-PD-1 monoclonal antibody, as first-line treatment for patients with non-squamous non-small cell lung cancer. [Innovent Biologics] Press Release Spectrum Pharmaceuticals, Inc. announced that it has initiated two new cohorts for first-line, locally advanced or metastatic non-small cell lung cancer (NSCLC) patients with EGFR or HER2 exon 20 insertion mutations in its current Phase II NSCLC clinical trial. [Spectrum Pharmaceuticals, Inc.] Press Release Amgen and AstraZeneca announced that the FDA has granted Breakthrough Therapy Designation for tezepelumab in patients with severe asthma without an eosinophilic phenotype. [Amgen] Press Release Loxo Oncology, Inc. announced that the FDA has granted Breakthrough Therapy Designation to LOXO-292, a selective RET inhibitor, for the treatment of patients with metastatic RET-fusion-positive non-small cell lung cancer who require systemic therapy and have progressed following platinum-based chemotherapy and an anti-PD-1 or anti-PD-L1 therapy. [Loxo Oncology, Inc.] Press Release Merck announced that the FDA has accepted for review and granted priority review to a new supplemental Biologics License Application seeking approval for KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for first-line treatment of locally advanced or metastatic nonsquamous or squamous non-small cell lung cancer in patients whose tumors express PD-L1 without EGFR or ALK genomic tumor aberrations. [Merck & Co., Inc.] Press Release | |
| |
POLICY NEWSEurope’s Academics Fail to Report Results for 90% of Clinical Trials European academics are failing abysmally when it comes to reporting the results of clinical trials, a study has revealed. An analysis of data from the European Union’s Clinical Trial Register — published in The BMJ — shows that around 50% of the listed trials have not complied with guidelines that say results must be reported within 12 months. [Nature News] Editorial Prominent Health Policy Researcher Resigns from Dartmouth Over Plagiarism Dispute Dr. H. Gilbert Welch, one of the country’s top health care policy scholars, has resigned from his faculty position at Dartmouth College, after an investigation by the school concluded that he had committed research misconduct. [STAT News] Editorial Peer Reviewers in Developing Nations Are Underrepresented, Report Suggests Combined, scientists spend nearly 70 million hours peer reviewing manuscripts for scholarly journals every year, a new report says. But too much of the onus rests on researchers in wealthy countries, according to the report by the company Publons—based in London and Wellington—which enables researchers to track and claim credit for the peer reviews they perform. [ScienceInsider] Editorial
| |
EVENTSNEW IASLC Asia Conference on Lung Cancer 2018 Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Fellow – Sepsis and Pulmonary Injury Research (University of Maryland) Postdoctoral Research Fellow – Respiratory Epithelial Cell Biology (STEMCELL Technologies Inc.) Postdoctoral Scientist – Cancer Biology and Immunology (Technical University of Munich) PhD Students – Lung Disease Research (Justus-Liebig-Universität Gießen) Faculty Investigators – Cancer Research (The University of Alabama at Birmingham) Postdoctoral Position – Lung Diseases (German Research Center for Environmental Health) Postdoctoral Position – Acute Lung Injury (University of Kentucky) Cancer Research Scholar – Lung Cancer (University of California, San Francisco) Principal Investigators – Cancer (University of Alabama Birmingham) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Pulmonary Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|